Please assess the completion status of the following clinical trial:

Trial Title: Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of chronic obstructive pulmonary disease~2. Relatively stable airway obstruction with a post-bronchodilator FEV1\< 80% of predicted normal and a post-bronchodilator FEV1/FVC \<70%~3. Male or female patients, 40 years of age or older~4. Smoking history of more than 10 pack years~5. Ability to perform technically acceptable pulmonary function tests and maintain records~6. Ability to inhale medication in a competent manner from the RESPIMAT Inhaler and from a metered dose inhaler (MDI)~Exclusion criteria:~1. significant disease other than COPD~2. clinically relevant abnormal lab values~3. history of asthma~4. diagnosis of thyrotoxicosis~5. diagnosis of paroxysmal tachycardia~6. history of myocardial infarction~7. unstable or life-threatening cardiac arrhythmia~8. Hospitalization for heart failure within the past year~9. known active tuberculosis~10. malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years~11. history of life-threatening pulmonary obstruction~12. history of cystic fibrosis~13. clinically evident bronchiectasis~14. history of significant alcohol or drug abuse~15. history of thoracotomy with pulmonary resection~16. oral or patch ß-adrenergics~17. oral corticosteroid medication at unstable doses~18. regular use daytime oxygen therapy for more than one hour per day~19. Pulmonary rehabilitation program in the six weeks prior to the screening visit~20. Investigational drug within one month or six half lives (whichever is greater) prior to screening visit~21. Known hypersensitivity to ß-adrenergic drugs, BAC, EDTA~22. Pregnant or nursing women~23. Women of childbearing potential not using a highly effective method of birth control~24. Patients who have previously been randomised in this study or are currently participating in another study~25. Patients who are unable to comply with pulmonary medication restrictions prior to randomisation

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tiotropium+olodaterol FDC low dose (Type: EXPERIMENTAL): tiotropium+olodaterol FDC low dose; 2 inhalations once daily (a.m. dosing)
- tiotropium+olodaterol FDC high dose (Type: EXPERIMENTAL): tiotropium+olodaterol FDC high dose; 2 inhalations once daily (a.m. dosing)
- tiotropium low dose (Type: ACTIVE_COMPARATOR): tiotropium low dose; 2 inhalations once daily (a.m. dosing)
- tiotropium high dose (Type: ACTIVE_COMPARATOR): tiotropium high dose; 2 inhalations once daily (a.m. dosing)
- olodaterol (Type: ACTIVE_COMPARATOR): one dose only; 2 inhalations once daily (a.m. dosing)
- placebo (Type: PLACEBO_COMPARATOR): 2 inhalations once daily (a.m. dosing)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete